Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Sep;47(3):245-54.
doi: 10.1002/pbc.20895.

Blood safety and the choice of anti-hemophilic factor concentrate

Leonard A Valentino  1 , Veeral M Oza
Affiliations
Review

Blood safety and the choice of anti-hemophilic factor concentrate

Leonard A Valentino et al. Pediatr Blood Cancer. 2006 Sep.

Abstract

Hemophilia is a congenital disorder due to the deficiency of the activity of factor VIII (classical hemophilia A) or IX (Christmas disease or hemophilia B). Bleeding is common and may result in long-term complications or even death. Bleeding may be treated or prevented by infusion of factor concentrates however these drugs are not without risk. Clinicians often feel ill prepared to provide accurate and impartial information regarding these drugs. This review will provide the reader with an historical yet up to date perspective on blood safety as it relates to the choice of concentrates to treat hemophilia.

PubMed Disclaimer

Comment in

References

    1. MASAC recommendations concerning the treatment of hemophilia and other bleeding disorders . National Hemophilia Foundation; 2003. Nov 2003. Report nr 151.
    1. Clinical Practice Guidelines . Hemophilia and von Willebrand's Disease (2. Management; Update 2): Association of Hemophlia Clinic Directors of Canada; 1999. July 1999. Report.
    1. Pierce GF, Lusher JM, Brownstein AP, et al. The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy. JAMA 1989; 261: 3434–3438. - PubMed
    1. Brooker M. Treatment Products Supply Update. Safety and Supply News. Vol. 2002 (ed 1): World Federation of Hemophilia; 2002. - PubMed
    1. Giangrande PL. Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002; 8: 19–22. - PubMed